ประสิทธิผลและความปลอดภัยของมะระขี้นกแคปซูลร่วมกับยาเบาหวานแผนปัจจุบัน ในการรักษาผู้ป่วยเบาหวานชนิดที่ 2 ที่ไม่สามารถควบคุมระดับน้ำตาลในเลือดได้: ประสิทธิผลของมะระขี้นกแคปซูลในการรักษาผู้ป่วยเบาหวานชนิดที่ 2

Teerawit Klaytae

Authors

Teerawit Klaytae Department of Social medicine, Buddhachinaraj Phitsanulok Hospital 65000

Keywords:

momordica charantia L, type 2 diabetes mellitus, blood sugar levels

Abstract

Bitter melon (Momordica charantia) has been recognized for its potential to regulate blood glucose levels and may complement standard diabetestreatment. This non-randomized trial aimed to evaluate the effectiveness and safety of bitter melon capsules in patients with type 2 diabetes who had inadequate blood sugar control despite using conventional medications at Ban Krang and Ban Laem Pho Subdistrict Health Promotion Hospitals in Phitsanulok. A study enrolled 60 participants, assigned into two groups. Each group consisted of 30 patients. The experimental group received 500 mg bitter melon capsules, taking two capsules before meals, in the morning and evening, along with their existing medications continuously for 12 weeks. The control group continued with standard diabetes medications alone. Analysis blood sugar, kidney and liver function using ANCOVA revealed that, post-treatment, the experimental group had significantly lower blood sugar levels by 25.83 mg/dL and HbA1c by 0.68% compared with control group (p < 0.05). However, the liver and kidney function level did not differ. These findings suggest that bitter melon capsules in conjunction with standard medication are more effective in reducing both blood sugar levels than standard medication alone and safe for clinical use

References

Diabetes Association of Thailand. Clinical practice guideline for diabetes. Bangkok, thailand: Srimuang Printing; 2023. (in Thai)

Department of Disease Control. Annual report 2022, Division of Non-Communicable Diseases. Bangkok, thailand:: Aksorn Graphic and Design; 2022. (in Thai)

Potisat S, Krairittichai U, Jongsareejit A, Sattaputh C, Arunratanachote W. A 4-year prospective study on long-term complications of type 2 diabetic patients: the Thai DMS diabetes complications (DD.Comp.) project. J Med Assoc Thai 2013;96(6):637-43.

Institute of Medical Research & Technology Assessment. Literature review: Current situation and service models for chronic non-communicable diseases. Bangkok, thailand: Art Qualify; 2014. (in Thai)

Richardson CR, Borgeson JR, Van Harrison R, Wyckoff JA, Yoo AS, Aikens JE, et al. Management of type 2 diabetes mellitus [Internet]. Ann Arbor (MI): Michigan Medicine University of Michigan; 2021 [cited 2024 May 20] Available from: URL: https://www.ncbi.nlm.nih.gov/books/NBK579413/pdf/Bookshelf_NBK579413.pdf

Phongwetcharak J. Essential knowledge about insulin [Internet]. [cited 2024 May 20]. Available from: URL: https://pharm.tu.ac.th/uploads/pharm/pdf/articles/pocketbook%20edit2.pdf

Titus M, Shi L. Containing the rising cost of insulin: Select policy recommendations. Glob Health J 2019;3(4):84-8.

Phiman W, Poolbut P. Effects of bitter melon (Momordica charantia) in the treatment of diabetes mellitus: Mechanism of action and clinical effectiveness [Internet]. 2017 [cited 2024 May 20]. Available from: URL: https://ccpe.pharmacycouncil.org/index.php?option=article_detail&subpage=article_detail&id=143

Liu Z, Gong J, Huang W, Lu F, Dong H. The Effect of Momordica charantia in the Treatment of Diabetes Mellitus: A Review. Evid Based Complement Alternat Med 2021;2021:3796265. doi: 10.1155/2021/3796265.

Cicek SS. Momordica charantia L.- Diabetes-related bioactivities, quality control, and safety considerations. Front Pharmacol 2022;13:904643. doi: 10.3389/fphar.2022.904643

Khanna P, Jain SC, Panagariya A, Dixit VP. Hypoglycemic activity of polypeptide-p from a plant source. J Nat Prod 1981;44(6):648–55.

Yang YS, Wu NY, Kornelius E, Huang CN, Yang NC. A randomized, double-blind, placebo-controlled trial to evaluate the hypoglycemic efficacy of the mcIRBP-19-containing Momordica charantia L. fruit extracts in the type 2 diabetic subjects. Food Nutr Res 2022;66:3685. doi: 10.29219/fnr.v66.3685

Krawinkel MB, Ludwig C, Swai ME, Yang RY, Chun KP, Habicht SD. Bitter gourd reduces elevated fasting plasma glucose levels in an intervention study among prediabetics in Tanzania. J Ethnopharmacol 2018;216:1-7. doi: 10.1016/j.jep.2018.01.016

Sotanaphun U, Trakoon-Osot W, Komindr S. Effect of Thai bitter gourd (Momordica charantia L.) on liver and renal function in type 2 diabetic patients. Nakhon Pathom, Thailand: Faculty of Pharmacy, Silpakorn University; 2011.

Rosner B. Fundamentals of biostatistics. 5th ed. Duxbery, Massachusetts State, USA: Duxbury Thomson Learning; 2000.

Suthar AC, Pai VG, Kadam Y, Tongaonkar A, Kale S, Deshpande AB, et al. Efficacy and safety of PDM011011 capsules as compared to metformin in subjects with type-2 diabetes mellitus: An open-label, randomized, active-controlled, multicentric, phase III study. JDM 2016;6(1):38-48.

Fuangchan A, Seubnukarn T, Jungpattanawadee D, Sonthisombat P, Ingkaninan K, Plianbangchang P, et al. Retrospective study on the use of bitter melon for type 2 diabetes at Dansai Crown Prince Hospital, Thailand. SRIMEDJ 2009;24(4):332-8.

Zanker KS, Mang B, Hahn A. Personalized diabetes and cancer medicine: A rationale for anti-diabetic nutrition (bitter melon) in a supportive setting. Curr Cancer Ther Rev 2012;8(1):66-77.

Punikhom P, Tiyaworanant S, Suriyakrai S. The glucose-lowering effects of the powder of Momordica charantia L. fruits on type 2 diabetic patients. J Thai Trad Alt Med 2016;14(1):46-58.

Butt B, Ghulam B, Bashir Z, Abbasi SR, Hussain S, Jadoon SK, et al. Enhanced creatinine level in diabetic patients maximizing the possibilities of nephropathy and its association with blood urea nitrogen and glomerular filtration rate. Cureus 2024;30:16(9):e70482. doi: 10.7759/cureus.70482

Fuangchan A, Sonthisombat P, Seubnukarn T, Chanouan R, Chotchaisuwat P, Sirigulsatien V, et al. Hypoglycemic effect of bitter melon compared with metformin in newly diagnosed type 2 diabetes patients. J Ethnopharmacol 2011;134(2):422-8.

American Diabetes Association Professional Practice Committee. Older adults: Standard of medical care in diabetes-2022. Diabetes Care 2022;45(Suppl 1):S195-S207.